The primary building block of the Eosomes is an engineered protein designed to incorporate all the required functionalities that provide efficient packaging and delivery of a therapeutic:

  • Receptor Binding & Uptake Peptide: This peptide acts as a homing signal to deliver the Eosomes to a specific disease cell based on a lock and key recognition of a receptor on the cell surface.
  • Membrane Penetration and Intracellular Trafficking Peptide: This peptide mediates active escape from the endosome and penetration of the Eosomes to the inside of the cell where the packaged therapeutic is released in a concentrated fashion.
  • Therapeutic Binding Peptide: This peptide is designed to capture the therapeutic and allow assembly of the Eosomes.

The specific DNA sequences encoding the various functional peptides are cloned in frame into a bacterial expression vector allowing the Eosomes protein to be produced and purified as a full length functional entity.

When the protein is combined with a designated therapeutic, the protein captures the therapeutic through noncovalent interaction, triggering spontaneous self-assembly into the Eosomes without any additional extrinsic manipulation.

Both the receptor binding peptide and therapeutic binding peptide are modular and can be readily modified to adapt the Eosomes to deliver different therapeutics to different tissues.  This versatility represents a unique feature of our Eosomes technology and positions it as a platform technology applicable to multiple disease areas and therapeutic modalities.

click image to enlarge

Properties of the Eosomes

  • Self-assembling nanoparticles (<50nm) comprised of two components: a single multifunctional polypeptide (targeting peptide, membrane penetration peptide, therapeutic capturing peptide); a therapeutic payload.
  • Eosomes can package a variety of therapeutics including; small molecule therapeutics, single or double strand oligonucleotides, siRNA, mRNA, and plasmid DNA.
  • Eosomes actively target disease cells through attachment to a selected cell surface receptor and internalize through receptor-mediated endocytosis.
  • Eosomes mediate active endosomal lysis to allow delivery the therapeutic payload to the interior of a target cell, avoiding lysosomal degradation.
  • The size and composition of the Eosomes allows improved EPR (Enhanced Penetration and Retention). 
  • Eosomes can be readily adapted to deliver a therapeutic to many different tissue types.
  • Eosomes are very stable in circulation.
  • Eosomes are currently administered through intravenous injection.